HIF1A and cancer: A drug that inhibits HIF-2α dimerization with ARNT (without affecting HIF-1α) is currently in development.105 But direct, HIF-1-specific inhibition is not possible yet, despite active interest in targeting HIF-1 signaling in cancer.103, 106, 107